Drug Profile
Research programme: metabolic disorders kinase inhibitors - Arrien Pharmaceuticals
Alternative Names: ARN-2089Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Arrien Pharmaceuticals
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Obesity in USA
- 04 Nov 2017 No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA
- 17 Sep 2012 Early research is ongoing in USA